Table 4.

Summary of GLP-1 RA initial therapy and monotherapy Phase 3 clinical trials.

GLP-1 RAs	Dose	FPG (mg/dl)	PPG (mg/dl)	HbA1c (%)	Weight loss (kg)	References
Exenatide BID (Byetta®)	10 μg BID	−18.7	−24.7	−0.9	−3.1	[133]
Lixisenatide (Lyxumia®/Adlyxin®)	10 μg for 2 wks then 20 μg	−19.8	−98.5	−0.85	−2	[134]
	10 μg for wk 1, 15 μg for wk 2, then 20 μg	−16.2	−81.2	−0.73	−2	[134]
Liraglutide (Victoza®)	1.2 mg	−14.4	−30.6	−0.84	−2.1	[135]
	1.8 mg	−25.2	−37.8	−1.14	−2.5	[135]
Semaglutide (Ozempic®)	0.5 mg	−45	N. A.	−1.45	−3.7	[71]
	1.0 mg	−41.4	N. A.	−1.55	−4.53
Dulaglutide (Trulicity®)	0.75 mg	−26	−41.4	−0.71	−2.36	[136]
	1.5 mg	−29	−43.4	−0.78	−2.29	[136]
Albiglutide (Tanzeum®/Eperzan®)	30 mg	−34	N. A.	−0.84	−0.4	[137]
	50 mg	−43	N. A.	−1.04	−0.9	[137]
Exenatide QW (Bydureon®)	2 mg	−41.4	N. A.	−1.53	−2.0	[138]

Abbreviations: FPG: fasting plasma glucose level; PPG: postprandial plasma glucose level; HbA1c: level of hemoglobin A1c; BID: twice a day; QW: once a week; N. A.: information is not available.